ESR1 and breast cancer: In a South Korean cohort of 229 patients with ER+ and Her2- breast cancer, TP53 was found mutated in 10% of the patients [19], compared to 16.7% in ‘luminal A and luminal B/Her2- combined’ in our cohort.